Pulmozyme®

On November 27, 2024, Finadiet signed an agreement with Roche, under which it assumed the commercialization of Pulmozyme®, Dornase alfa, in the Argentine pharmaceutical market starting in 2025.

Pulmozyme® is a drug that has been on the global pharmaceutical market for more than 20 years and is recognized for its usefulness in the treatment of Cystic Fibrosis.

Pulmozyme is imported by:
Productos Roche S.A.Q. e I.
Rawson 3150 (B1610BAL), Ricardo Rojas, Tigre, Pcia. de Buenos Aires.
To obtain the Prescribing Information, visit: https://www.roche.com.ar/soluciones/productos IInformation intended exclusively for healthcare professionals.
M-AR-00005168

Pulmozyme is imported by:
Laboratorio Finadiet S.A.C.I.F.I.

Derrumal®

Derrumal 300 has been licensed to sell in Argentina for 25 years. Market leadership position. More than 650,000 treatments sold annually. Among the top 30 products with the highest sales in the pharmaceutical industry.

Derrumal® 300 has become the company's flagship product, demonstrating our strong commitment and involvement with our business partners.

Derrumal® 300/Piascledine 300 has remained the best-selling international brand e terapéutica en los últimos 10 años (IQVIA 2023) in its therapeutic class over the past 10 years (IQVIA 2023).